European Commission approves first treatment for peanut allergy
Aimmune Therapeutics' PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
List view / Grid view
Aimmune Therapeutics' PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
Nestlé Health Science will acquire Aimmune Therapeutics for a total value of $2.6 billion, extending the former's food allergy portfolio.